NCT00256139已完成3 期
CLEAR Study: Clinical Experience Acquired With Raptiva Study
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 793
- 试验地点
- 1
研究概览
简要总结
A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered Raptiva in the treatment of patients with moderate to severe psoriasis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Plaque psoriasis covering ³10% of total BSA (see Appendix A)
- •Diagnosis of psoriasis for at least 6 months
- •A minimum PASI score of 12.0 at screening (see Appendix A)
- •Patients who are either not controlled by, intolerant to or contraindicated to at least 2 currently available systemic therapies (e.g., photochemotherapy (PUVA), cyclosporin, corticosteroids, methotrexate, oral retinoids, MMF, thioguanine, hydroxyurea, sirolimus, azathioprine, 6 MP) (defined as "high need" patients)
- •Body weight <= £120 kg
- •18 to 75 years old
- •For women of childbearing potential, use of an acceptable method of contraception to prevent pregnancy and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study
- •Willingness to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources during the study
- •Willingness to enter Study
排除标准
- •Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
- •History of severe allergic or anaphylactic reactions to humanised monoclonal antibodies or fusion proteins that contain an Ig Fc region
- •Clinically significant psoriasis flare during screening or at the time of enrollment
- •History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection
- •History of opportunistic infections (e.g., systemic fungal infections, parasites)
- •Seropositivity for human immunodeficiency virus (HIV) Patients will undergo mandatory testing at screening. Patients who are positive for HIV will be excluded.
- •Pregnancy or lactation
- •WBC count <4000/mL or >14,000/mL
- •Seropositivity for hepatitis B or C virus Patients will undergo testing during screening. Patients who are positive for hepatitis B antigen or hepatitis C antibody will be excluded.
- •Hepatic enzymes ³3 times the upper limit of normal
- •History of active tuberculosis (TB) or currently undergoing treatment for TB PPD testing or chest X-ray is required for high risk patients (see Appendix I). Patients with a positive PPD (not due to BCG vaccination) or chest X-ray will be excluded.
- •Presence of malignancy within the past 5 years, including lymphoproliferative disorders Patients with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
- •Previous treatment with Raptiva (anti-CD11a)
- •Diagnosis of hepatic cirrhosis, regardless of cause or severity
- •Serum creatinine ³2 times the upper limit of normal
- •Hospital admission for cardiac disease, stroke, or pulmonary disease within the last year
- •History of substance abuse within the last 5 years
- •Any medical condition that, in the judgment of the investigator, would jeopardize the patient's safety following exposure to study drug
- •Note: Restrictions and/or directions apply to the following treatments during specified time periods prior to initial study drug administration and during the study:
- •Systemic therapy for psoriasis (within 28 days prior to Study Day 0)
- •Systemic immunosuppressive drugs for other indications (within 28 days prior to Study Day 0)
- •Topical therapies for psoriasis (within 14 days prior to Study Day 0)
- •Live or killed virus or bacteria vaccines (within 14 days prior to Study Day 0)
- •Other vaccines or allergy desensitisation (it is recommended that these are scheduled at least 14 days prior to Day 0 or ³3 months after the last injection of study drug)
- •Other experimental drugs or treatments (within 28 days or five half lives, whichever is longer, prior to Day 0) b Blockers, ACE inhibitors, interferons, quinidine, antimalarial drugs, or lithium (if clinically indicated, such medications are allowed but the dosage should be held constant from Day -28 throughout the study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT02504645ImmuPharma202
已完成
3 期
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary Angioedema (HAE)NCT02584959Shire75
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)Plaque PsoriasisNCT01722331Sun Pharmaceutical Industries Limited772
进行中（未招募）
3 期
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerHER2-positive Breast CancerNCT06316531Sichuan Baili Pharmaceutical Co., Ltd.274
已完成
3 期
A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT01995201Hoffmann-La Roche401